Brief: Medicenna Therapeutics Says Il4r Patients Survived Twice As Long As Approved Treatments
25/09/2019 13:47
Sept 25 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA PRESENTS PROMISING UPDATE FROM ITS MDNA55
CLINICAL
TRIAL IN RECURRENT GLIOBLASTOMA AT THE TARGETING INNATE IMMUNITY
CONGRESS
* MEDICENNA THERAPEUTICS CORP - PATIENTS TREATED AT HIGH
DOSE SHOW
IMPRESSIVE SURVIVAL BENEFIT
* MEDICENNA THERAPEUTICS CORP - IL4R POPULATION SURVIVING
TWICE AS
LONG AS CURRENT APPROVED TREATMENTS
Source text for Eikon: ID:nCNW9pPmta
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results